Activation of immune blood biomarkers from interferon gamma pathway distinguished long term survivors (>=2 years) from ...

Company finalizing preparations for end of January 2026 U.S. FDA Biologics License Application (BLA) submission for OST-HER2 ...

Expert Rev Anticancer Ther. 2009;9(4):511-523. With current standard treatment, including multiagent chemotherapy and surgical resection, 70% of patients with localized osteosarcoma are cured.

While novel targeted biological therapies are critically needed in osteosarcoma therapy, conventional cytotoxic chemotherapy agents are still likely to be heavily relied upon in the coming years.

A major driver of the bone cancer osteosarcoma has been discovered by researchers from UCL, EMBL EBI and the Royal National Orthopaedic Hospital, providing insights that could help to predict cancer ...

Sorafenib, gamma-secretase inhibitor, and bortezomib as potential therapeutic agents for hepatoblastoma. Background: We report data of long term follow up of 883 patients with localized osteosarcoma ...

Researchers published a new study, “Ongoing chromothripsis underpins osteosarcoma genome complexity and clonal evolution,” in Cell that they say solves the mystery of what drives the genomic ...

Researchers have been able to identify at least three distinct subtypes of a rare type of bone cancer for the first time, which could transform clinical trials and patient care. While genetic ...